Journal of Oncology Research and Treatment
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Short Communication   
  • Adv Oncol Res Treat 2016. 1:1,

Quo Vadis, Cardio-Oncology?

Nebigil CG1, Tounsi N2, Fuhrmann G3 and Désaubry L2,4*
1Department Cardiology, GPCRs in Cardiobiology Team, University of Strasbourg-CNRS, France
2Department Pharmacy, Laboratory of Therapeutic Innovation, Faculty of Pharmacy, University of Strasbourg-CNRS, France
3Department Pharmacy, Laboratory of Biophotonics and Pharmacology, Faculty of Pharmacy, University of Strasbourg-CNRS, France
4Department Medicinal Chemistry, Sino-French Joint Lab of Food Nutrition/Safety and Medicinal Chemistry, Tianjin University of Science and Technology, China
*Corresponding Author : Désaubry L, Department of Medical Chemistry, Laboratory of Therapeutic Innovation (UMR 7200), Faculté De Pharmacie De L' Université De Strasbourg 74 Route Du Rhin 67401 Illkirch Cedex, France, Tel: (+33) 03 68 85 41 41, Fax: (+33) 03 68 85 43 10, Email: desayubry@unistra.fr

Received Date: Mar 07, 2016 / Accepted Date: Mar 17, 2016 / Published Date: Mar 24, 2016

Citation: Nebigil CG, Tounsi N, Fuhrmann G, Désaubry L (2016) Quo Vadis, Cardio-Oncology?. Adv Oncol Res Treat 1: 102.

Copyright: ©2016 Nebigil CG, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top